Nurlaela Arief N, Gustomo Aurik, Rahman Roestan M, Putri Aghnia Nadhira Aliya, Islamiaty Muthya
School of Business and Management, Institut Teknologi Bandung, West Java, Indonesia.
PT. Bio Farma, Bandung, West Java, Indonesia.
Heliyon. 2022 Aug 18;8(8):e10347. doi: 10.1016/j.heliyon.2022.e10347. eCollection 2022 Aug.
This paper aims to explore core competencies and analyze the digital leveling implementation of Pharma 4.0 in Indonesian Pharmaceutical companies.
This study uses a mixed-method Delphi study conducted in the first two rounds. The first and second rounds aimed to determine the core competencies of the Pharmaceutical Industry to face the Pharma 4.0 era. In the first round, FGD was conducted involving 12 participants, and semi-structured interviews were carried out with 10 participants in the second round. Alongside Delphi, this research also employs NVIVO as a tool for content analysis. Furthermore, in the third round, a survey was conducted to determine the leveling of the digital implementation of Pharma 4.0, involving 215 senior management participants representing 34 national pharmaceutical industries.
The study revealed eight core competencies needed by human capital in the pharmaceutical industry to face the Pharma 4.0 era: critical thinking, bioinformatics, entrepreneurial thinking, digital skills, intrapreneurial skills, research skills, regulatory compliance, and data ethics. Regarding digital leveling implementation, this study found five main levels: level 1 (simplification), level 2 (automatization), level 3 (integrated system), level 4 (digital transformation), and level 5 (disease prediction). This study also affirms that most of the pharmaceutical industries in Indonesia are at level 2 (mean = 4.2) and level 1 (mean = 4.0). Several pharmaceutical industries are at level 3 (mean = 3.5), and a few others are at level 4 (mean 3.2) and level 5 (mean = 1.4).
This study is the first to analyze the leveling of digital implementation in Pharma 4.0. The results showed that core competencies could be used as a benchmark to develop employee skills. This current study provides the essential data for core competency development and digital leveling implementation for the pharmaceutical industry and government in preparing Pharma 4.0.
本文旨在探索核心竞争力,并分析印度尼西亚制药公司中制药4.0的数字化水平实施情况。
本研究采用在前两轮进行的混合方法德尔菲研究。第一轮和第二轮旨在确定制药行业应对制药4.0时代所需的核心竞争力。在第一轮中,进行了焦点小组讨论(FGD),有12名参与者参与,在第二轮中对10名参与者进行了半结构化访谈。除了德尔菲法,本研究还采用NVIVO作为内容分析工具。此外,在第三轮中,进行了一项调查以确定制药4.0数字化实施的水平,涉及代表34家全国制药行业的215名高级管理人员。
该研究揭示了制药行业人力资本应对制药4.0时代所需的八项核心竞争力:批判性思维、生物信息学、创业思维、数字技能、内部创业技能、研究技能、法规合规性和数据伦理。关于数字化水平实施,本研究发现了五个主要水平:1级(简化)、2级(自动化)、3级(集成系统)、4级(数字化转型)和5级(疾病预测)。本研究还证实,印度尼西亚的大多数制药行业处于2级(平均 = 4.2)和1级(平均 = 4.0)。一些制药行业处于3级(平均 = 3.5),其他一些处于4级(平均 = 3.2)和5级(平均 = 1.4)。
本研究首次分析了制药4.0中数字化实施的水平。结果表明,核心竞争力可作为培养员工技能的基准。本研究为制药行业和政府在准备制药4.0时进行核心竞争力发展和数字化水平实施提供了重要数据。